NEW YORK (GenomeWeb News) – Houston-based startup Castle Biosciences has signed an option agreement to license a biomarker-based brain cancer test from the University of Texas MD Anderson Cancer Center.
 
The firm said that the test, which was developed and validated at MD Anderson in collaboration with other US institutions, could potentially predict a patient’s likelihood to respond to standard treatment based on the cancer’s genetic footprint. It said that it would provide more details on the test in the near future.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.